Introduction
Ophthalmic Graves' disease may develop in the abscence of clinical or biochemical evidence of thyrotoxicosis and because ofits immunological basis, autoimmune ophthalmopathy has been suggested as a better name.' As the disease may represent a distinct autoimmune disorder,2 different forms of treatment aimed at immunomodulation have been used, such as steroids, azathioprine, cyclophosphamide, irradiation, plasmapheresis, and cyclosporin. Response to these treatments is variable and none is uniformly successful. '3-7 We describe a patient with steroid-resistant autoimmune ophthalmopathy which responded dramatically to cyclophosphamide and a two week course of orbital irradiation. As far as we are aware, the successful use of this combination has not been previously reported.
Case report
A 26 year old female was referred in September 1983 with bilateral painful proptosis, chemosis and double vision. Three and a half months before admission pain, swelling and redness of the right eye developed. This was followed a month later by diplopia and proptosis of both eyes.
On examination, she had mild proptosis and severe chemosis. The visual axes were parallel but there was asymmetrical restriction of eye movements in all directions of gaze, the most affected being right lateral gaze. Visual acuity, fields, blind spot and optic fundi were all normal. Computed tomographic (CT) scan showed gross swelling of the extra-ocular muscles particularly of the left medial and lateral recti ( Figure 1) .
Routine blood tests were normal. Serum thyroxine (T4) was 80 nmol/l (normal range 58-154 nmol/1), Triiodothyronine (T3) uptake 29.9% (range 25-35%). Thyroglobulin and thyroid microsomal antibody titres were less than 1:10 and 1:100 respectively. The baseline thyroid stimulating hormone (TSH) was 1.0 mU/l and showed a normal rise to 4.4 mU/l thirty minutes after the i.v. injection of thyrotrophin releasing hormone (TRH) (0.2 mg).
Prednisone 40 mg/day was started. Initially the pain, proptosis and chemosis subsided though the diplopia persisted. Figure  2a, 2b) . Initially, the right eye was in the neutral position but with further deterioration became fixed in adduction. Seven months after presentation, as prednisone was both ineffective and producing unacceptable side effects, the dose was reduced to 7.5 mg/day and cyclophosphamide (1 mg/kg/day) added with radiation of the orbits, sparing the lens (2000 cGy in ten fractions over 13 days).
The chemosis and proptosis subsided; the restriction of extra-ocular movements gradually improved.
Five months after irradiation and on the same dose of cyclophosphamide and prednisone, the visual axes were now parallel; diplopia was now only present in the extremes of lateral gaze due to fibrotic shortening ofboth medial recti muscles (Figure 3a, 3b) . A CT scan showed a marked reduction in size of the extraocular muscles ( Figure 4) . After 13 months, cyclophosphamide was stopped and prednisone reduced to 2.5 mg a day. There has been no deterioration since.
Discussion
This patient exhibited all the features of autoimmune ophthalmopathy: chemosis, proptosis, limitation of eye movements and the pathognomonic CT changes of extraocular muscle swelling.8
The exact pathogenesis of the disease is unclear, but both systemic as well as local orbital immunological processes have been implicated. The evidence includes the binding to extra-ocular muscles of immune complexes of thyroglobulin and its antibodies6, the finding of circulating antibodies directed against an antigen derived from oculomotor muscle9 and ofT-cell mediated cytotoxicity to human ocular muscles. 5 Treatment regimes have therefore been designed to counteract these processes and include the use of steroids, immunosuppressive agents, irradiation, plasmapheresis, and cyclosporin.3 However, the response to any of the above methods is variable. Steroids and irradiation in combination was reported to have a slightly better reponse than steroids alone.4 While cyclosporin was effective in some patients,5 in others, clinical deterioration developed during treatment. 7 Recently, antibodies reacting with plasma membrane of extraocular muscles have been isolated from patients with Graves' ophthalmopathy,2 suggesting that there may be similarities to auto-immune myasthenia gravis. In the latter condition, cyclophosphamide and whole-body irradiation were curative in experimental myasthenia in mice.'0 By analogy, the same regime was employed here, except that the irradiation was confined to the orbits and within 5 months, eye movements had completely recovered apart from limited abduction because offibrosis ofthe medial rectus muscles.
Thus low dose cyclophosphamide and orbital irradiation can be effective in autoimmune ophthalmopathy; muscle involvement when present may be particularly responsive to this combined therapy. In the doses used, no side effects were observed. 
